A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A phase 2 trial of INCB123667 in ovarian cancer, run by Incyte Corporation, now recruiting.
Overview
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 2 interventional study registered as NCT07023627 by Incyte Corporation, with 160 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-04-27. Interventions recorded: INCB123667. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
Phase
Phase 2
Sponsor
Incyte Corporation
Registry
Enrolled
160